Edition:
India

Presbia PLC (LENS.OQ)

LENS.OQ on NASDAQ Stock Exchange Global Market

2.59USD
2:29am IST
Change (% chg)

$0.43 (+19.91%)
Prev Close
$2.16
Open
$2.23
Day's High
$2.59
Day's Low
$2.23
Volume
3,698
Avg. Vol
4,127
52-wk High
$5.79
52-wk Low
$1.86

Summary

Name Age Since Current Position

Mark Yung

43 2017 Executive Chairman of the Board

Todd Cooper

50 2015 President, Chief Executive Officer, Director

Jarett Fenton

39 2016 Chief Financial Officer, Secretary

John Strobel

2015 Vice President of Sales

Gerd Auffarth

2015 Director

Robert Cresci

73 2015 Director

Gerald Farrell

2016 Director

Vladimir Feingold

66 2017 Director

Zohar Loshitzer

57 2015 Director

Ressler Richard

56 2015 Director

Biographies

Name Description

Mark Yung

Mr. Mark T. Yung is Chairman of the Board of the Company. He is a co-founder and managing principal at OCV Management, LLC (“OCV”), an investment adviser based in Los Angeles California, which was co-founded by Mr. Yung and Richard Ressler, a member of our board and our majority stockholder, in 2016. Previously, Mr. Yung served as Managing Director at Orchard Capital Corporation (“Orchard Capital”), an investment firm affiliated with Mr. Ressler and located in Los Angeles, California, a firm he joined in 2006. Through his affiliation with OCV and Orchard Capital, Mr. Yung has and continues to serve in various senior capacities for companies in which OCV, Orchard Capital or their respective affiliates invest, including as Executive Chairman of Environmental Solutions Worldwide, Inc., as CFO and director of Polymer Plainfield Holdings, Inc., and as Chairman of Vantage Surgical Systems, Inc. Prior to Orchard Capital, Mr. Yung was a Senior Vice President in the Corporate Strategy and Merger and Acquisitions groups of Citigroup and ABN AMRO. Previously, Mr. Yung was an investment professional at JPMorgan Partners, where he focused on venture capital, growth equity and buyout transactions in Latin America and was a board member of various emerging companies. Mr. Yung is a Director of PacWest Bancorp, Inc. (NASDAQ: PACW). Mr. Yung holds a B.A. from Cornell University and an MBA from INSEAD. Neither Mr. Yung nor Mr. Loshitzer will be compensated directly by the Company for their services. Pursuant to the terms of a services agreement between the Company and OCV, the Company will pay OCV in shares of restricted stock, with an aggregate value of $250,000 per year. Contingent upon Messrs. Cooper and Thurman each executing a general release and waiver agreement (the “Release”) containing customary releases of claims, Messrs.

Todd Cooper

Mr. Todd Cooper is Chief Executive Officer, President, Director of Presbia Public Limited Company, since January 2015. From July 2011 to November 2014, Mr. Cooper served as the Chief Executive Officer of NVISION, which operates a network of ophthalmological surgical centers. From October 2008 to June 2010, Mr. Cooper served as the Vice President of Marketing and the General Manager of Henry Schein Medical, a division of Henry Schein, Inc., a global provider of health care products and services to office-based practitioners. Prior to that, Mr. Cooper served as: the Senior Vice President, Global Sales and Marketing of Discus, a global manufacturer of dental products (2003 to 2008); a Senior Vice President of IMG Holdings, (1997-2003); the Director of Marketing at The Franklin Mint, (1995 to 1997); and the Senior Marketing Manager at Canadian Tire Corporation, Limited, (1993 to 1995).

Jarett Fenton

Mr. Jarett Fenton is Chief Financial Officer, Secretary of the Company. Prior to joining us, Mr. Fenton served as Vice President of Finance and Senior Controller of Alphaeon, Inc., a privately held healthcare technology company, from December 2013 to June 2016. From January 2011 to December 2013, Mr. Fenton served as a partner at Orchid Capital Partners, providing SEC and capital markets consulting services to several client companies. During that time, from April 2012 to December 2012, Mr. Fenton also served as Chief Financial Officer of Ciralight Global, Inc., a publicly held company manufacturing daylighting systems for OEM partners including Firestone and Eaton. From February 2007 until December 2010, Mr. Fenton served as Chief Financial Officer of Enova Systems, Inc., a publicly-held company that manufactured proprietary vehicle drive systems for clean vehicle applications. He previously served from March 2003 through February 2007 as the Chief Executive of the Clarity Group, a company he founded to provide SEC reporting and corporate compliance consulting services. Through Clarity Group, Mr. Fenton provided consulting services to Enova Systems, from 2006 until he was appointed as Chief Financial Officer of Enova in February 2007. From September 1998 to March of 2003, Mr. Fenton worked as a Senior Associate in the Middle Market practice of PricewaterhouseCoopers in the Orange County, CA office where he facilitated audit engagements, worked on SEC reporting issues, controls assessments, client reporting, financial guidance interpretation and staff development. Mr. Fenton has a B.A. in Business Economics with an emphasis in Accounting from the University of California at Santa Barbara and is a Certified Public Accountant in the State of California.

John Strobel

Mr. John Strobel is Vice President of Sales of the Company. Mr. Strobel has extensive background in international sales and ophthalmology. He most recently served as Vice President of Sales and Marketing of Western Enterprises. Prior to that, Mr. Strobel served as Vice President of Sales and Marketing for Volk Optical, a diagnostic and surgical device manufacturer in the ophthalmology and optical markets. Over his 12 years at the firm, he built a global selling team in over 100 countries and drove 12 consecutive years of record revenues and increase in net profit as well as opening new offices and managing teams in India, China, Latin America, Europe, Middle East/Africa, and Australia. Earlier in his career, Mr. Strobel served in sales management roles at Hu-Friedy, a $100 million dental manufacturer and Depuy/Motech Spinal Systems. Mr. Strobel earned a Bachelor of Science in Biomedical Engineering from Tulane University and a Master of Business Administration in International Management from Thunderbird School of Global Management.

Gerd Auffarth

Dr. Gerd Auffarth, M.D., Ph.D., is Director of the Company. Dr. Auffarth is Director of the International Vision Correction Research Centre (IVCRC) and The David J. Apple International Laboratory for Ophthalmic Pathology. Dr. Auffarth has his M.D. degree from RWTH Aachen Medical School, Aachen University of Technology in Germany. Dr. Auffarth’s core research is in cornea, corneal surgery, presbyopia, cataracts and intraocular lens implants. His expertise is in IOL’s, multi-focal IOL’s, refractive laser technologies and presbyopia surgery. Dr. Auffarth is considered a pioneer in Femtosecond laser surgery. In an article published by The Ophthalmologist Dr. Auffarth was ranked among the top 20 ophthalmologists in the world.

Robert Cresci

Mr. Robert J. Cresci is Director of Company. He has served as a director of Presbia PLC since March 2015. He has been a managing director of Pecks Management Partners Ltd., an investment management firm, since 1990. Mr. Cresci currently serves on the boards of j2 Global, Inc., Luminex Corporation, OFS Capital Corporation, CIM Commercial Trust Corporation, and several private companies. Mr. Cresci previously served on the board of Continucare Corporation until 2011 and the board of Sepracor, Inc. until 2009. By virtue of his time with Pecks Management Partners and the other business entities mentioned, Mr. Cresci brings to our board of directors his broad expertise and experience in accounting issues, and public company matters. Mr. Cresci holds an undergraduate degree in Engineering from the United States Military Academy at West Point and holds a M.B.A. in Finance from the Columbia University Graduate School of Business.

Gerald Farrell

Dr. Gerald Farrell, Ph.D., is Director of Presbia Public Limited Company. Dr. Farrell has been involved in the pharmaceutical industry for more than 25 years, and worked for Eli Lilly Company Limited in Ireland and the United Kingdom for the majority of his successful career. Dr. Farrell’s tenure at Eli Lilly included positions of Managing Director, leading the commercial sales and marketing in Ireland where he launched several major products in Europe; Director Strategy, Commercial and Business in the UK accountable for long-term strategic planning and business operations as well as other positions related to compliance, production, sales, and planning. Dr. Farrell earned a Ph.D. Plant Biotechnology from University College, Cork, and a BSc Honours – Plant Science and Higher Diploma Education with Honours from University College, Galway. Dr. Farrell serves on the Board for UCD Michael Smurfit Graduate Business School, serves as a director, and previously served as president, for Irish Pharmaceutical Healthcare Association, and serves as a council member for the Dublin Chamber of Commerce. Previously, from 2003 until 2014, Dr. Farrell served as a director of Eli Lilly and Company (Ireland) Ltd.

Vladimir Feingold

Mr. Vladimir Feingold is Director of Presbia Public Limited Company. He has served as the Chief Technology Officer and as a director of Presbia Holdings since September 2009, the Chief Technology Officer of Presbia PLC since February 2014 and an Executive Vice President of Presbia PLC since June 2014, and he commenced serving as a director of Presbia PLC in January 2015. He has more than 30 years’ experience as an executive in the medical technology field and in research and development. Beginning in September 2001, he was the Chief Executive Officer of Visitome, Inc. and Biovision AG until Biovision AG was liquidated in bankruptcy in Switzerland in 2008 and the operations of Visitome were merged into Presbia in 2009. Previously, Mr. Feingold served as President and Chairman of Staar Surgical AG, Switzerland (1994-1999) and held positions of increasing responsibility with its parent, Staar Surgical Co., a U.S. public company (1991-1999). From 1995 to 2000, Mr. Feingold was also a director of Canon-Staar, Japan, and from 1984 to 2001, Mr. Feingold was managing director and chairman of the board of Bionica Pty Ltd., Australia. From 1975 to 1984, Mr. Feingold held various research, engineering and manufacturing executive positions at Telectronics Pty. Ltd., Australia.

Zohar Loshitzer

Mr. Zohar Loshitzer is an Director of the Company., , effective September 30, 2015. he is no longer Chief Business Development Officer of Presbia Public Limited Company. He has served as the President and Chief Executive Officer and a director of Presbia Holdings since May 2007, served as the Chief Executive Officer of Presbia PLC from February 2014 to October 2014, served as the President of Presbia PLC from February 2014 to January 2015 and has served as a director of Presbia PLC since February 2014. Mr. Loshitzer assumed the position of Chief Business Development Officer of Presbia PLC upon Mr. Cooper’s election as the Chief Executive Officer and President of Presbia PLC in January 2015. Since January 2005, Mr. Loshitzer has served as a principal at Orchard Capital. he has served since August 2000 as the President and Chief Executive Officer of Universal Telecom Services, Inc. He has served as Executive Vice President of Corporate Strategy of j2 Global since June 2001 and from July 1997 through June 2001 he served as the Chief Information Officer at j2 Global. Mr. Loshitzer was the founder and President of MTP Consulting, Inc., from January 2011 to August 2013, and he was the founder and President of Imali, Inc., from January 2007 to December 2010. Since 1995, he has been a Managing Director at Orchard Telecom. He previously served as a consultant to MAI Systems Corporation, a provider of information technology solutions, and as a General Manager and Managing Director at Life Alert Emergency Response, Inc. which Mr. Loshitzer co-founded. He has been a director of the publicly-traded Advanced Cell Technology Inc. since December 2011 and publicly-traded Environmental Solutions Worldwide, Inc. since January 2011. He graduated from Tel Aviv University with a degree in Electronic Engineering.

Ressler Richard

Mr. Richard S. Ressler is a Director of Presbia Public Limited Company, since January 2015. He has served as an officer and a director of Presbia Holdings since May 2007 and commenced serving as a director of Presbia PLC in January 2015. Mr. Ressler serves on the board of Presbia Holdings pursuant to a services agreement between our company and Orchard Capital Corporation (“Orchard Capital”). Mr. Ressler is the founder, owner and President of Orchard Capital, (including Presbia). He has been President of Orchard Capital since 1994. Mr. Ressler has been Chairman of the Board of Directors of j2 Global, Inc. (“j2 Global”), since 1997, and served as j2 Global’s Chief Executive Officer from 1997 to 2000. Since March 2014, Mr. Ressler has been Chairman of the Board of Directors of CIM Commercial Trust Corporation. Through an agreement with Orchard Capital, Mr. Ressler serves in various senior capacities with, among other companies, CIM Group, L.P. (together with its affiliates, “CIM Group”) co-founded by Mr. Ressler, and Orchard First Source Asset Management (together with its affiliates, “OFSAM”) co-founded by Mr. Ressler. Both OFSAM and its wholly owned subsidiary, OFS Capital Management, LLC, are registered with the U.S. Securities and Exchange Commission as registered investment advisers. Mr. Ressler also serves as a board member for various private companies in which Orchard Capital or its affiliates invest. Mr. Ressler holds a B.A. from Brown University and J.D. and M.B.A. degrees from Columbia University.

Basic Compensation